ALISKIREN
Last year saw the introduction of a direct renin antagonist (RA), the first new class of antihypertensive medications to enter the market in more than a decade.
New molecular entities (NMEs), as defined by the FDA, are new drug products that have as their active ingredient a chemical substance marketed for the first time in the United States.